Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients
October 2025
in “
Figshare
”
Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.
Studysummary This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer